What is Neopred (prednisolone)?

What is Neopred (Prednisolone)?

Neopred is a brand name for prednisolone, a synthetic glucocorticoid medication with potent anti-inflammatory and immunosuppressive properties used to treat a wide range of inflammatory and autoimmune conditions. 1

Pharmacological Classification and Mechanism

Prednisolone is a synthetic adrenocortical steroid with predominantly glucocorticoid properties that reproduces and amplifies the physiological actions of endogenous corticosteroids. 1 The drug exerts its therapeutic effects through multiple anti-inflammatory pathways:

• Inhibition of inflammatory processes including edema, fibrin deposition, capillary dilatation, leukocyte migration, and phagocytosis 1
• Induction of T cell apoptosis through modulation of cell signaling pathways 2
• Suppression of interleukin transcription and stabilization of the NFκB complex 2
• Inhibition of arachidonic acid metabolism and stimulation of lymphocyte apoptosis in the gut lamina propria 2

Pharmacokinetics

Prednisolone is rapidly and well absorbed from the gastrointestinal tract following oral administration, with 70-90% protein binding in plasma and a half-life of 2-4 hours. 1 The drug is metabolized primarily in the liver and excreted in urine as sulfate and glucuronide conjugates. 1

Clinical Applications

Prednisolone is indicated for numerous conditions requiring potent anti-inflammatory therapy:

Inflammatory Bowel Disease

• For moderate to severe ulcerative colitis flares, oral prednisolone starting at 40 mg daily induces remission in 77% of patients within 2 weeks, compared to 48% with sulfasalazine alone 2
• The optimal dose is 40 mg/day for outpatient management, as 60 mg/day causes significantly more adverse events without added benefit 2
• Corticosteroids have no role in maintenance therapy for either ulcerative colitis or Crohn's disease 2

Autoimmune Hepatitis

• The standard induction regimen is prednisolone 30 mg/day (reducing to 10 mg/day over 4 weeks) plus azathioprine 1 mg/kg/day, which achieves remission in approximately 80% of patients 2
• Higher initial doses up to 1 mg/kg/day may result in more rapid normalization of transaminases but carry greater risk of steroid-related side effects 2
• Treatment should continue for at least 2 years and for at least 12 months after normalization of transaminases 2

Vasculitis and Severe Autoimmune Disease

• For ANCA-associated vasculitis, the standard initial dose is 0.5-1 mg/kg/day (maximum 60-80 mg/day) 3
• In severe presentations with organ-threatening disease, IV pulse methylprednisolone 500-1000 mg/day for 3 days should precede oral therapy 3

Important Safety Considerations

Common Adverse Effects

• Side effects occur in 10-45% of patients depending on dose, with headache, nausea, epigastric pain being most common 2
• Severe adverse effects occur mainly at doses >20 mg/day for more than 18 months, including cosmetic changes (weight gain, facial rounding, hirsutism), diabetes, emotional instability, hypertension, and osteoporosis 2
• Approximately 15% of patients require treatment discontinuation due to severe adverse effects 2

Bone Health Protection

• All patients receiving prolonged corticosteroid therapy should receive calcium and vitamin D supplementation 2
• DEXA scanning should be performed at 1-2 yearly intervals while on steroids, with active treatment of osteopenia and osteoporosis 2
• Bisphosphonates are recommended for patients >65 years or those with history of fragility fracture 2

Critical Pitfalls to Avoid

• Too rapid dose reduction can be associated with early relapse, and doses <15 mg/day are ineffective for active disease 2
• Never use corticosteroids for maintenance therapy in inflammatory bowel disease, as they provide no benefit and only accumulate toxicity 2
• In elderly patients with multiple comorbidities, cardiac disease, or diabetes, prednisolone carries markedly increased risk of serious adverse events including mortality 4

Dosing Considerations by Age

In elderly patients (65-89 years), plasma prednisolone concentrations are higher due to impaired metabolic clearance, yet paradoxically these patients show less suppression of endogenous cortisol, suggesting reduced sensitivity to the drug's effects. 1 This necessitates careful dose titration and heightened monitoring in frail elderly patients. 2